☆ 4.6 Article

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

CANCERS (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline

Smith Apisarnthanarax et al.

Summary: This guideline provides evidence-based recommendations for external beam radiation therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, covering indications, techniques, outcomes, and emphasizing multidisciplinary care. Future studies should focus on defining the role of EBRT in the context of liver directed and systemic therapies.

PRACTICAL RADIATION ONCOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?

Alessandro Rizzo et al.

Summary: The paper reviews the combination of lenvatinib plus pembrolizumab for advanced HCC treatment, emphasizing the potential benefits and future treatment directions. Expert opinion suggests that the landscape of new agents and combinations is expanding positively based on promising results of early phase clinical trials.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)

Add to Collection

Review Gastroenterology & Hepatology

Epidemiology of Hepatocellular Carcinoma

Katherine A. McGlynn et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), is a major global health concern. While HBV and HCV remain important risk factors for HCC, efforts in vaccination and treatment are showing promise. However, the increasing prevalence of metabolic risk factors like obesity and diabetes, as well as other factors like excessive alcohol consumption, present ongoing challenges in the prevention of liver cancer.

HEPATOLOGY (2021)

Add to Collection

Article Oncology

Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival

Lara Hilal et al.

Summary: The study retrospectively analyzed outcomes of HCC patients treated with liver radiation therapy, finding that ablative RT can achieve over 90% local control in inoperable patients while minimizing tumor-and treatment-related liver failure, leading to improved survival.

JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Review Oncology

Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies

Xiufeng Liu et al.

Summary: Hepatocellular carcinoma is a common cancer with poor prognosis in unresectable cases. Recent studies show that combination therapy with atezolizumab and bevacizumab could be a promising future standard treatment option for these patients.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Oncology

Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy

Brian De et al.

Summary: This study aimed to differentiate the effects of proton and photon radiotherapy on absolute lymphocyte count in hepatocellular carcinoma (HCC) patients. Results showed that patients receiving proton therapy had higher ALC nadir and longer OS. Multivariable analysis revealed that Grade 3 or higher lymphopenia and other factors were associated with higher risk of death.

JOURNAL OF HEPATOCELLULAR CARCINOMA (2021)

Add to Collection

Article Oncology

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Arndt Vogel et al.

Summary: This study conducted indirect comparisons of treatments for first-line locally advanced or metastatic unresectable HCC patients who had not received prior systemic treatment. Results showed that atezolizumab-bevacizumab had improved overall survival compared to other treatment options, indicating its potential superiority for these patients.

LIVER CANCER (2021)

Add to Collection

Review Gastroenterology & Hepatology

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy

Eva Rajha et al.

GASTROENTEROLOGY REPORT (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment

Nicolas Palaskas et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial

Thomas Yau et al.

JAMA ONCOLOGY (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma

Tian-ming Cui et al.

ONCOTARGETS AND THERAPY (2020)

Add to Collection

Article Oncology

Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma

Hwa Kyung Byun et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2019)

Add to Collection

Article Oncology

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

T Yau et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Review Gastroenterology & Hepatology

Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma

Chien Pong Chen

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

Add to Collection

Article Oncology

Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer

Brant A. Inman et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Medicine, General & Internal

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Anthony B. El-Khoueiry et al.

LANCET (2017)

Add to Collection

Article Oncology

Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus

Emma B. Holliday et al.

CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2017)

Add to Collection

Review Oncology

Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance

Christopher H. Crane et al.

CANCER (2016)

Add to Collection

Article Oncology

Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

Stuart A. Grossman et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)

Add to Collection

Article Oncology

Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma

Tae Hyun Kim et al.

STRAHLENTHERAPIE UND ONKOLOGIE (2014)

Add to Collection

Article Gastroenterology & Hepatology

Hepatocellular carcinoma review: Current treatment, and evidence-based medicine

Ali Raza et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2014)

Add to Collection

Article Oncology

Efficacy, Safety, and Biomarkers of Single- Agent Bevacizumab Therapy in Patients with Advanced Hepatocellular Carcinoma

Valerie Boige et al.

ONCOLOGIST (2012)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Stereotactic body radiation therapy: The report of AAPM Task Group 101

Stanley H. Benedict et al.

MEDICAL PHYSICS (2010)

Add to Collection

Article Oncology

Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411

Christopher H. Crane et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

Add to Collection

Article Oncology

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

Abby B. Siegel et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.